Analyst firms · Morgan Stanley · ARGX

Morgan Stanley ARGX price target and rating history

argenx SE (ARGX) · Health Care

Morgan Stanley rates argenx SE (ARGX) Overweight with a $700 price target, as of its latest action on Jul 3, 2025. It has published 7 rating actions on ARGX since August 2021, including 1 upgrade and 1 downgrade. Across 3 firms with a ARGX price target in the last 12 months, the median target is $1,185.

Current rating
Overweight
Price target
$700
Median target, all firms
$1,185
Actions on ARGX
7

Morgan Stanley price target on ARGX

$700$487$27420222023202420252026
Morgan Stanley price target on ARGX, each point a stated target, August 2021 to July 2025.

Every Morgan Stanley rating on ARGX

How other firms rate ARGX

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
UBSBuy$1,400Aug 26, 2026
Deutsche BankHoldAug 24, 2026
GuggenheimBuy$1,185Aug 4, 2026
Robert W. BairdNeutral$858Dec 18, 2025
Wolfe ResearchPeer PerformNov 24, 2025

Questions about Morgan Stanley and ARGX

What is Morgan Stanley's price target for ARGX?
Morgan Stanley's latest stated price target for argenx SE (ARGX) is $700, from its action on Jul 3, 2025.
What is Morgan Stanley's rating on ARGX?
Morgan Stanley rates ARGX Overweight, a bullish rating, as of Jul 3, 2025.
When did Morgan Stanley last change its view on ARGX?
On Jul 3, 2025, Morgan Stanley resumes coverage at Overweight, price target $700.
How does Morgan Stanley's ARGX target compare with other analysts?
Across 3 firms with a ARGX price target in the last 12 months, the median target is $1,185.

More ARGX rating histories

All Morgan Stanley ratingsARGX news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.